KedRAB Approval History
- FDA approved: Yes (First approved August 23rd, 2017)
- Brand name: KedRAB
- Generic name: rabies immunoglobulin human
- Dosage form: Injection
- Company: Kamada Ltd. and Kedrion S.p.A.
- Treatment for: Rabies Prophylaxis
KedRAB [rabies immunoglobulin (human)] is a human plasma derived anti-rabies immunoglobulin indicated for post-exposure prophylaxis (PEP) of rabies infection.
Development History and FDA Approval Process for KedRAB
|Aug 25, 2017||FDA Approves KedRAB [rabies immune globulin (Human)] for Post-Exposure Prophylaxis of Rabies Infection|
|Sep 1, 2016||Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.